These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
262 related articles for article (PubMed ID: 33790681)
1. Complement in Sickle Cell Disease: Are We Ready for Prime Time? Varelas C; Tampaki A; Sakellari I; Anagnostopoulos Α; Gavriilaki E; Vlachaki E J Blood Med; 2021; 12():177-187. PubMed ID: 33790681 [TBL] [Abstract][Full Text] [Related]
2. Complement in sickle cell disease and targeted therapy: I know one thing, that I know nothing. Tampaki A; Gavriilaki E; Varelas C; Anagnostopoulos A; Vlachaki E Blood Rev; 2021 Jul; 48():100805. PubMed ID: 33504459 [TBL] [Abstract][Full Text] [Related]
3. Delayed hemolytic transfusion reaction/hyperhemolysis syndrome in children with sickle cell disease. Talano JA; Hillery CA; Gottschall JL; Baylerian DM; Scott JP Pediatrics; 2003 Jun; 111(6 Pt 1):e661-5. PubMed ID: 12777582 [TBL] [Abstract][Full Text] [Related]
4. Complement activation during intravascular hemolysis: Implication for sickle cell disease and hemolytic transfusion reactions. Merle NS; Boudhabhay I; Leon J; Fremeaux-Bacchi V; Roumenina LT Transfus Clin Biol; 2019 May; 26(2):116-124. PubMed ID: 30879901 [TBL] [Abstract][Full Text] [Related]
5. Long-term Use of Eculizumab for Prolonged Hemolysis Following a Delayed Hemolytic Transfusion Reaction in Pediatric Sickle Cell: A Case Report. Noda C; Sisler I J Pediatr Pharmacol Ther; 2022; 27(6):569-572. PubMed ID: 36988996 [TBL] [Abstract][Full Text] [Related]
6. Successful Outcome of Hyperhemolysis in Sickle Cell Disease following Multiple Lines of Treatment: The Role of Complement Inhibition. Vlachaki E; Gavriilaki E; Kafantari K; Adamidou D; Tsitsikas D; Chasapopoulou E; Anagnostopoulos A; Tsapas A Hemoglobin; 2018; 42(5-6):339-341. PubMed ID: 30626228 [TBL] [Abstract][Full Text] [Related]
7. Delayed Hemolytic Transfusion Reaction in a Sickle Cell Disease Patient: A Case Report. Saleh M; Mallipeddi VP; Ali A Cureus; 2020 Dec; 12(12):e12167. PubMed ID: 33489579 [TBL] [Abstract][Full Text] [Related]
8. Two Consecutive Episodes of Severe Delayed Hemolytic Transfusion Reaction in a Sickle Cell Disease Patient. Mpinganzima C; Haaland A; Holm AGV; Thein SL; Tjønnfjord GE; Iversen PO Case Rep Hematol; 2020; 2020():2765012. PubMed ID: 32351743 [TBL] [Abstract][Full Text] [Related]
9. Complement activation in sickle cell disease: Dependence on cell density, hemolysis and modulation by hydroxyurea therapy. Roumenina LT; Chadebech P; Bodivit G; Vieira-Martins P; Grunenwald A; Boudhabhay I; Poillerat V; Pakdaman S; Kiger L; Jouard A; Audureau E; Pirenne F; Galactéros F; Frémeaux-Bacchi V; Bartolucci P Am J Hematol; 2020 May; 95(5):456-464. PubMed ID: 31990387 [TBL] [Abstract][Full Text] [Related]
11. Lactate dehydrogenase and hemolysis index to predict vaso-occlusive crisis in sickle cell disease. Feugray G; Dumesnil C; Grall M; Benhamou Y; Girot H; Fettig J; Brunel V; Billoir P Sci Rep; 2023 Dec; 13(1):21198. PubMed ID: 38040880 [TBL] [Abstract][Full Text] [Related]
12. Current challenges in the management of patients with sickle cell disease - A report of the Italian experience. Russo G; De Franceschi L; Colombatti R; Rigano P; Perrotta S; Voi V; Palazzi G; Fidone C; Quota A; Graziadei G; Pietrangelo A; Pinto V; Ruffo GB; Sorrentino F; Venturelli D; Casale M; Ferrara F; Sainati L; Cappellini MD; Piga A; Maggio A; Forni GL Orphanet J Rare Dis; 2019 May; 14(1):120. PubMed ID: 31146777 [TBL] [Abstract][Full Text] [Related]
13. How we treat delayed haemolytic transfusion reactions in patients with sickle cell disease. Gardner K; Hoppe C; Mijovic A; Thein SL Br J Haematol; 2015 Sep; 170(6):745-56. PubMed ID: 25967919 [TBL] [Abstract][Full Text] [Related]
14. Markers of endothelial dysfunction and leucocyte activation in Saudi and non-Saudi haplotypes of sickle cell disease. Al Najjar S; Adam S; Ahmed N; Qari M Ann Hematol; 2017 Jan; 96(1):141-146. PubMed ID: 27686084 [TBL] [Abstract][Full Text] [Related]
15. Incidence and predictive score for delayed hemolytic transfusion reaction in adult patients with sickle cell disease. Narbey D; Habibi A; Chadebech P; Mekontso-Dessap A; Khellaf M; Lelièvre JD; Godeau B; Michel M; Galactéros F; Djoudi R; Bartolucci P; Pirenne F Am J Hematol; 2017 Dec; 92(12):1340-1348. PubMed ID: 28924974 [TBL] [Abstract][Full Text] [Related]
17. Delayed Hemolytic Transfusion Reaction in a Patient with Sickle Cell Disease: Case Report. Omer SA; Alaesh JS; Algadeeb KB Int Med Case Rep J; 2020; 13():307-311. PubMed ID: 32801941 [TBL] [Abstract][Full Text] [Related]
18. Antibiotics to modify sickle cell disease vaso-occlusive crisis? Stewart C; Jang T; Mo G; Mohamed N; Poplawska M; Egini O; Dutta D; Lim SH Blood Rev; 2021 Nov; 50():100867. PubMed ID: 34304939 [TBL] [Abstract][Full Text] [Related]
19. Beneficial Effects of Soluble Guanylyl Cyclase Stimulation and Activation in Sickle Cell Disease Are Amplified by Hydroxyurea: In Vitro and In Vivo Studies. Ferreira WA; Chweih H; Lanaro C; Almeida CB; Brito PL; Gotardo EMF; Torres L; Miguel LI; Franco-Penteado CF; Leonardo FC; Garcia F; Saad STO; Frenette PS; Brockschnieder D; Costa FF; Stasch JP; Sandner P; Conran N J Pharmacol Exp Ther; 2020 Sep; 374(3):469-478. PubMed ID: 32631869 [TBL] [Abstract][Full Text] [Related]
20. Anti-s antibody-associated delayed hemolytic transfusion reaction in patients with sickle cell anemia. Kalyanaraman M; Heidemann SM; Sarnaik AP; Meert KL; Sarnaik SA J Pediatr Hematol Oncol; 1999; 21(1):70-3. PubMed ID: 10029818 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]